Myriad Genetics Inc (MYGN) Investment Analysis
Myriad Genetics Inc. is a leading molecular diagnostic and precision medicine company that develops and commercializes genetic and genomic tests designed to assess disease risk, guide treatment decisions, and monitor disease progression across high-value clinical specialties.[1, 2, 3] The company operates primarily within the clinical laboratory testing services sector, where it generates revenue by processing patient specimens ordered by healthcare providers and billing commercial third-party insurers, government programs such as Medicare and Medicaid, and patients directly.[3] While its commercial operations are heavily concentrated in the United States, Myriad has systematically expanded its global footprint, establishing select international commercial partnerships and laboratory operations in key markets, most notably in Japan.[3, 4]
The company's commercialized product suite is organized across three primary clinical specialties: the Cancer Care Continuum, Prenatal Health, and Mental Health.[5] The Cancer Care Continuum comprises advanced oncology assays such as the MyRisk Hereditary Cancer test, Prolaris prostate cancer prognostic test, myChoice CDx companion diagnostic, and the newly launched Precise Molecular Residual Disease (MRD) assay.[5, 6] Prenatal Health is anchored by reproductive screening tests, including the Prequel non-invasive prenatal screen (NIPS), the Foresight carrier screen, and the FirstGene Multiple Prenatal Screen.[7] Mental Health is centered on the GeneSight Psychotropic test, a category-leading pharmacogenomic test that analyzes how genetic variations affect an individual’s metabolism and clinical response to psychiatric medications.[2, 8, 9]
The primary customer base for Myriad’s services comprises clinical specialists, including oncologists, obstetricians and gynecologists (OB/GYNs), psychiatrists, and primary care physicians, who operate within private practices, hospital networks, and academic medical centers.[3, 10] The underlying end markets are structurally supported by secular trends in personalized healthcare, clinical guidelines recommending early genetic risk screening, and biopharmaceutical integration of companion diagnostics to select target patient populations for targeted therapies.[3, 11]
Healthcare providers choose Myriad Genetics over competing diagnostic laboratories because of its deep clinical validation, proprietary genomic database compiled over three decades, and comprehensive billing infrastructure.[3, 12, 13] The company's tests are integrated into leading electronic medical record (EMR) platforms, such as Epic and Flatiron Health’s OncoEMR, which significantly reduces ordering friction and embeds Myriad directly into the clinician’s daily workflow, creating high switching costs.[13, 14, 15]
Myriad Genetics commercializes specialized tests tailored to specific clinical workflows.[3] The Cancer Care Continuum is anchored by the MyRisk Hereditary Cancer test, a 63-gene panel that assesses germline risk for 11 hereditary cancers, including breast, ovarian, and colorectal cancers, by identifying clinically actionable pathogenic mutations.[14] This test is paired with RiskScore, a polygenic risk assessment tool that utilizes a comprehensive set of single nucleotide polymorphisms (SNPs) to estimate five-year and lifetime breast cancer risk for women of all ancestries.[16, 17, 18] For localized prostate cancer, the Prolaris biopsy test measures the expression of cell cycle progression genes to determine tumor aggressiveness, allowing clinicians to distinguish between patients who can safely undergo active surveillance and those who require immediate treatment.[5, 19]
In prenatal health, the company is transitioning toward FirstGene, an in-house, 4-in-1 prenatal cell-free DNA (cfDNA) assay that evaluates maternal carrier status, fetal aneuploidy risk (including chromosomes 13, 18, 21, and sex chromosome copy number variations), feto-maternal RhD blood type compatibility, and fetal recessive disease risk from a single maternal blood draw, eliminating the immediate need for a paternal sample.[7, 20, 21]
In the mental health segment, the GeneSight Psychotropic test analyzes 15 genes to predict an individual's metabolic and clinical response to over 60 common medications prescribed for depression, anxiety, and attention deficit hyperactivity disorder (ADHD).[2, 8, 9]
The technological mechanisms powering these assays range from targeted hybridization capture-based next-generation sequencing (NGS) and cell-free DNA amplification using proprietary AMPLIFY technology to combinatorial pharmacogenomic algorithms that analyze multi-gene-drug interactions rather than single-gene variations.[8, 20, 21]
Myriad Genetics possess a narrow economic moat driven by two primary sources: proprietary variant classification databases and high workflow-related customer switching costs.[3, 13] Following the 2013 landmark U.S. Supreme Court ruling that invalidated raw human gene patents, competition transitioned from raw DNA sequences to clinical interpretation.[13, 19] Over thirty years, Myriad has compiled a vast, proprietary database of genetic mutations and clinical correlations.[12, 13] This allows the company to classify variants of uncertain significance (VUS) at a far lower rate than newer competitors, providing clinicians with definitive answers rather than ambiguous findings.[13, 14]
Furthermore, the integration of Myriad’s ordering portals directly into leading EMR platforms embeds the company into the administrative and clinical routines of healthcare providers.[13, 14, 15] Once a clinical system configures its EMR to order and receive Myriad’s results natively, switching to another diagnostic lab introduces significant operational friction, staff retraining costs, and administrative overhead, which creates durable switching costs.[13, 14] Branded tests like GeneSight and MyRisk carry strong clinician mindshare, high Net Promoter Scores (NPS), and are backed by over 1,000 peer-reviewed scientific publications, making physicians more comfortable selecting Myriad’s tests to avoid clinical ambiguity.[10, 14, 22]
The total market opportunity across Myriad's active segments is estimated to be approximately \$40 billion, with the majority of these markets currently less than 50% penetrated.[18]
| Market Segment | Estimated TAM | Segment Drivers & Sub-Market Dynamics |
|---|---|---|
| Molecular Residual Disease (MRD) | \$21 Billion | Targeted by the Precise MRD assay; growing at 15-20% annually. Segmented into Breast (\$7B), Colorectal (\$5B), Ovarian/Endometrial (\$2B), and Renal (\$1B).[23] |
| Hereditary Cancer | \$7 Billion | Comprises the \$5B unaffected population (family history risk) and the \$2B affected population (therapy selection).[18] |
| Pharmacogenomics / Mental Health | Multi-Billion | Category-leading positioning with GeneSight targeting over 76 million individuals in the U.S. suffering from mental disorders.[8, 24] |
The molecular diagnostics market is highly competitive and fragmented.[13] In oncology and molecular residual disease, Myriad competes against Guardant Health (somatic oncology) and Natera (tumor-informed MRD).[13, 25, 26] In reproductive and prenatal health, Natera holds a leading position with its Panorama NIPS and Horizon carrier screen, directly competing with Myriad’s Prequel and FirstGene.[7, 25] Other direct competitors in hereditary cancer and reproductive testing include Ambry Genetics, GeneDx, NeoGenomics, and Quest Diagnostics.[13, 25, 26]
Myriad Genetics is currently holding ground in hereditary cancer, supported by its dedicated germline sales force and EMR integrations.[5, 27] In mental health, the company is gaining ground, with GeneSight demonstrating strong double-digit revenue growth (+24% year-over-year in Q1 2026) driven by superior reimbursement coverage.[5, 28] Conversely, Myriad has lost ground in prenatal health.[5, 25] The prenatal health segment experienced a 12% year-over-year volume drop in Q1 2026, stemming from system friction and customer disruptions during the transition to a new order management platform in mid-2025, allowing Natera and other competitors to capture adjacent market share.[5, 25, 29]
Myriad Genetics reported its financial results for the first quarter of fiscal year 2026, ended March 31, 2026, on May 5, 2026.[1, 5] The company posted a mixed quarter, characterized by modest top-line growth that fell slightly short of expectations, alongside a wider-than-anticipated bottom-line loss.[6, 28] Total revenue reached \$200.4 million, representing a 2.3% increase year-over-year but missing analyst expectations of \$202.39 million by 1%.[27, 28] The company reported an adjusted earnings per share (EPS) loss of \$0.09, missing the consensus forecast of an \$0.0706 loss by \$0.0194.[23, 28]
On a GAAP basis, Myriad's net loss widened significantly to \$34.1 million (or an EPS loss of \$0.36) compared to a near-breakeven position in Q1 2025.[5, 6] This drop was primarily driven by the absence of a prior-year discrete tax benefit and a \$5.4 million asset impairment charge, including a \$4.5 million write-down of the Women's Health reporting unit.[6]
The financial results illustrate the impact of Myriad's restructuring and strategic investments on near-term profitability.[23]
| Financial Metric | Q1 2026 Actual | Q1 2025 Actual | YoY Change (%) | Analyst Consensus | Beat / Miss Status |
|---|---|---|---|---|---|
| Total Revenue | \$200.4M | \$195.9M | +2.3% | \$202.39M | Miss (by 1.0%) [27, 28] |
| GAAP Net Loss | (\$34.1M) | ~\$0.0M | N/A | N/A | N/A [6] |
| Adjusted EPS | (\$0.09) | (\$0.03) | N/A | (\$0.0706) | Miss (by \$0.0194) [23, 28] |
| GAAP Gross Margin | 68.7% | 68.5% | +20 bps | N/A | N/A [28] |
| Adjusted EBITDA | (\$4.5M) | N/A | N/A | Near Breakeven | Miss [5, 29] |
| Cash Used in Ops | (\$15.7M) | (\$16.3M) | -3.7% | N/A | N/A [6] |
| Cash Balance | \$124.4M | \$149.6M (Q4'25) | -16.8% (QoQ) | N/A | N/A [6] |
The table below details segment-specific performance for the first quarter of 2026.[5]
| Product Category | Q1 2026 Revenue | Q1 2025 Revenue | YoY Change (%) | Q1 2026 Volume YoY Change | Core Dynamic & Driver |
|---|---|---|---|---|---|
| Cancer Care Continuum | \$120.2M | \$115.6M | +4.0% | +13% total (+14% hereditary) | Strong volume growth offset by shifts in product mix and average revenue per test.[5, 23] |
| Prenatal Health | \$41.9M | \$49.3M | -15.0% | -12% total | Severe headwinds from order system transition friction; volumes remain soft.[5] |
| Mental Health | \$38.3M | \$31.0M | +24.0% | +7% total | Strong reimbursement trends and higher average revenue per GeneSight test.[5, 30] |
Despite the Q1 2026 miss, management reaffirmed its full-year 2026 guidance:
* Total Revenue: \$860 million to \$880 million (midpoint reflects ~6% growth compared to FY 2025).[5, 31]
* Adjusted Gross Margin: 68% to 69%.[5]
* Adjusted EBITDA: \$37 million to \$49 million.[5]
Management noted that it expects sequential revenue growth to pick up in the second half of 2026, driven by a projected recovery in the prenatal health business and three milestone product launches (Precise MRD, FirstGene, and the AI-enabled Prolaris test).[5, 29, 30]
President and CEO Sam Raha highlighted that the Cancer Care Continuum is realizing returns from a dedicated hereditary cancer sales force.[5, 27] He noted that decisive steps are being taken to stabilize the prenatal business.[27] Additionally, the company has simplified its organizational structure and removed layers of management to improve operating agility, which required making headcount cuts.[28] To strengthen its advanced genomics leadership, the company appointed Brian Donnelly as Chief Commercial Officer (CCO), Vishal Sikri as SVP of Product, and Dr. Hussain Khorrammehr as SVP of Oncology R&D.[28]
The immediate market reaction to the Q1 2026 print on May 7, 2026, was severely negative, with the stock plunging 18.29% on the day of publication.[32] This reaction reflected investor disappointment over margin compression, ongoing cash burn, and the wider EPS loss.[30, 32] Over the subsequent weeks, however, the stock recovered, trading back up to \$5.99 by July 2, 2026.[33]
Sell-side analysts maintained a cautious stance.[34] The consensus rating remains a "Hold," with the average price target hovering around \$6.50 to \$7.17.[34, 35] Firms like UBS and Wells Fargo maintained neutral ratings, highlighting that while the pipeline (specifically Precise MRD) is promising, near-term execution and profitability concerns limit multiple expansion.[34, 35]
For long-term valuation, investors must look past near-term fluctuations to focus on the key structural drivers of the business:
* Historical Top-line Trajectory: Over the last five fiscal years, Myriad's revenue exhibits a low compound annual growth rate (CAGR) of 3.0% (moving from \$690.6 million in FY21 to \$824.5 million in FY25).[36] This sluggish growth is a direct consequence of stripping away legacy gene patents, divesting slow-growth segments, and navigating insurance coverage headwinds.[13, 15, 19]
* Asset Write-downs and Diluted Base: The company has accumulated a deficit of \$1.157 billion as of March 31, 2026.[5] Heavy past acquisitions led to large goodwill impairment charges (e.g., a \$316.7 million write-down in Q2 2025 and \$5.4 million in Q1 2026).[6, 37] This indicates historical capital destruction, which requires a steep discount on asset-based multiples.
* Balance Sheet Leverage & High Interest Costs: Myriad holds \$124.4 million in cash against \$120.3 million in long-term debt.[36] Its debt is tied to a \$125 million SOFR-based credit facility with an effective interest rate of 10.2% as of March 31, 2026.[6] Escalating monthly trailing twelve-month (TTM) revenue covenants (which commenced on Dec 31, 2025, at \$615 million and scale up quarterly) place severe operational constraints on the business.[6] Maintaining top-line expansion is essential to avoid technical default.[6]
Evaluating Myriad Genetics requires analyzing the specific vulnerabilities that could disrupt its path toward sustainable profitability.
Diagnostic testing operations rely heavily on friction-free customer interfaces.[3] The 12% drop in prenatal volume in Q1 2026 illustrates how minor electronic portal updates can disrupt physician workflows and drive orders to competing labs.[5, 29] Additionally, the success of the long-term investment thesis is highly dependent on successful market entries and timely commercialization of FirstGene and Precise MRD.[23, 29] Failure to secure physician adoption or to execute commercial sales plans for these launches would invalidate current growth projections.[38, 39]
The molecular diagnostics market is characterized by rapid innovation and pricing pressure.[13, 27] Competitors like Natera and Guardant Health possess larger R&D budgets and broader commercial footprints.[13, 26] If next-generation sequencing costs fall faster than Myriad can achieve internal laboratory efficiencies, gross margins will compress, leaving the company vulnerable to low-cost clinical providers.[13, 40]
Diagnostic laboratories are highly vulnerable to policy changes from private insurance payers.[15, 38] A prominent example is UnitedHealthcare's (UNH) policy update effective January 1, 2025, which discontinued commercial coverage for multi-gene pharmacogenetic tests, including GeneSight.[15] This change represented an annual headwind of approximately \$40 million (and \$10 million in Q3 2024 alone).[15] If other major commercial payers enact similar policies, Myriad's high-margin GeneSight revenue stream would face severe disruption.[15]
The FDA has signaled plans to increase its oversight of Laboratory-Developed Tests (LDTs), which historically bypassed premarket review.[20] Compliance with new FDA review cycles would delay product rollouts, escalate clinical trial costs, and increase operational overhead.[27, 39]
With a borrowing rate of 10.2%, interest expense eats into operating cash flows.[6] If revenues fall below escalating monthly TTM covenants (commencing at \$615 million and rising to \$974 million by 2029), lenders could declare a default, forcing a highly dilutive equity raise or restructuring.[6] Furthermore, past acquisitions have led to substantial goodwill impairment charges, demonstrating historically inefficient capital deployment.[6, 37]
The diagnostic industry is consolidating.[13] Large laboratory networks can leverage scale to offer broader testing panels at lower prices, squeezing independent specialty labs.[13, 40]
Because the term loan is SOFR-based, prolonged high-interest rate environments will keep debt service costs high, delaying the transition to positive free cash flow.[6] Additionally, wage inflation and rising supply chain costs for biological reagents could compress gross margins below the targeted 68-69% range.[5]
To monitor these dynamics, investors should distinguish between risk horizons:
* What could go wrong: Delays in securing clinical utility evidence for FirstGene or Precise MRD, resulting in slow commercial uptake.[7, 41]
* Early warning signs: Compression of gross margins below the 68% threshold, declining accounts ordering GeneSight, or cash balances dropping below \$100 million.[5, 6]
* What would most damage the thesis: Other major national insurance providers (like Aetna or Anthem) following UnitedHealthcare's policy change and excluding GeneSight commercial coverage, driving a covenant breach.[6, 15]
The five-year scenario projections model Myriad Genetics' transition from a restructuring business to a steady-state precision diagnostics provider.
The table below integrates the financial inputs to project total returns over the 5-year period.
| Scenario | Revenue in Year 5 (2031) | Margin / Earnings Assumption | Valuation Multiple Assumption | Current Share Price | Implied Future Share Price | 5-Year Total Return | Annualized Return | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | \$1,401M | 20.0% Adj. EBITDA | 1.8x EV/Revenue | \$5.99 USD | \$24.28 USD | +305.3% | 32.3% | 20% |
| Base Case | \$1,192M | 15.0% Adj. EBITDA | 1.25x EV/Revenue | \$5.99 USD | \$14.20 USD | +137.1% | 18.8% | 60% |
| Low Case | \$961M | 5.0% Adj. EBITDA | 0.6x EV/Revenue | \$5.99 USD | \$5.05 USD | -15.7% | -3.4% | 20% |
Using these inputs, the probability-weighted expected share price is calculated as follows:
$\text{Expected Value} = (\$24.28 \times 0.20) + (\$14.20 \times 0.60) + (\$5.05 \times 0.20) = \$4.86 + \$8.52 + \$1.01 = \mathbf{\$14.39\text{ USD}}$
ASYMMETRIC RETURN POTENTIAL
This section provides a qualitative evaluation of Myriad's business characteristics on a scale of 1 to 10.
Qualitative Scorecard Ratings (1-10)
=====================================
Management Alignment : [******----] 6
Revenue Quality : [*****-----] 5
Market Position : [*******---] 7
Growth Outlook : [*******---] 7
Financial Health : [****------] 4
Business Viability : [******----] 6
Capital Allocation : [*****-----] 5
Analyst Sentiment : [*****-----] 5
Profitability : [***-------] 3
Track Record : [****------] 4
-------------------------------------
Blended Score : [*****!----] 5.2 / 10
Following the April 2025 transition, President and CEO Sam Raha's total compensation is \$5.69 million USD, with \$3.99 million in equity awards, aligning his incentives with long-term share performance.[43, 44] Furthermore, directors and executives approved a new 2026 Equity Incentive Plan, supporting share-based compensation.[42] Recent insider buys, such as Sam Raha purchasing 40,000 shares in March 2026 and Chair Louise Phanstiel buying 104,507 shares in February 2026, indicate internal confidence.[26] However, legacy CEO Paul Diaz engaged in significant share sales (\$5.7M and \$401K in 2024) prior to stepping down, which remains a corporate governance overhang.[43, 45]
Myriad's diagnostic tests are transactional and performed once per patient.[3] The clinical relationships with ordering physicians provide recurring account-level volume, but the business is vulnerable to sudden reimbursement changes.[3] As seen with the UNH coverage policy change for GeneSight, a single payer decision can abruptly remove significant, high-margin revenue streams.[15]
The company maintains top-three market positions across most core segments.[18] MyRisk is a leading test in hereditary cancer, and GeneSight is a prominent diagnostic tool in psychiatric pharmacogenomics.[8, 14] However, the prenatal segment continues to lose ground to Natera due to ongoing order-system transition friction.[5, 25]
The growth profile is supported by the commercial launch of FirstGene and the entry of Precise MRD into the \$21 billion molecular residual disease market.[7, 23] These products target large, underpenetrated clinical opportunities.[18, 23]
While the net debt position is currently balanced, cash reserves declined by 16.8% sequentially in Q1 2026 to \$124.4 million USD.[6, 36] The company carries a \$125 million SOFR-based term loan at a high interest rate of 10.2%.[6] Additionally, strict monthly TTM revenue covenants limit operating flexibility.[6]
Myriad's tests offer clear clinical utility, backed by peer-reviewed literature and guideline recommendations.[13, 14] However, the business is vulnerable to reimbursement cuts and competitive technological advancements.[15, 27]
The company's historical capital allocation has been mixed.[3] Large acquisitions (such as Assurex for \$410 million and Counsyl for \$375 million) expanded Myriad's product offerings, but also led to substantial subsequent goodwill write-downs.[6, 19, 37]
Sell-side sentiment is neutral.[34] Most analysts rate the stock a "Hold," with price targets around \$6.50 to \$7.17 USD.[34, 35] Analysts acknowledge the potential of the pipeline but remain cautious due to ongoing bottom-line losses and execution overhangs.[34, 40]
Despite high gross margins of approximately 69%, the company remains unprofitable.[28, 40] Persistent GAAP operating losses (\$30.7 million in Q1 2026) are driven by heavy SG&A and R&D spending, alongside elevated debt-servicing costs.[5, 6]
Myriad pioneered BRCA-related hereditary cancer screening.[3, 19] However, since losing its patent exclusivity in 2013, the company has struggled to translate its clinical leadership into consistent shareholder value.[13, 19]
MODEST TRANSITION PROGRESS
Myriad Genetics represents a complex turnaround story within the precision medicine landscape.[3, 40] The company is actively working to transition from its historic reliance on a legacy hereditary cancer franchise toward a broader diagnostic footprint.[3] This strategy centers on high-TAM segments: the FirstGene prenatal screen, the GeneSight pharmacogenomic platform, and the newly launched Precise MRD assay.[8, 23, 29] If the company successfully executes these commercial rollouts, it stands to benefit from the growing adoption of personalized clinical screening.[11, 23]
The current valuation reflects significant investor skepticism regarding near-term profitability.[40] The stock's depressed multiple is a direct result of widening GAAP losses, ongoing operational cash burn, and the high-interest SOFR-based term loan.[6, 40] Additionally, the loss of UNH's commercial coverage for GeneSight represents a meaningful revenue headwind that complicates the company's path to positive cash flow.[15]
However, this valuation discount also creates asymmetric potential.[40] If the new executive leadership, led by Sam Raha, can stabilize the prenatal segment, manage SG&A expenses, and execute on the upcoming product launches, Myriad’s financial model could see operating leverage and margin expansion.[23, 27] For long-term investors, the core thesis depends on Myriad's ability to transition its clinical assets into a sustainable, cash-generating business model.[3, 40]
HIGH-EXECUTION TURNAROUND PLAY
Myriad Genetics' current share price of \$5.99 USD is trading well above its 200-day moving average of \$4.64 USD, signaling a constructive medium-term uptrend.[33, 46] The stock holds technical buy signals across short- and long-term moving averages, with near-term support established at the 50-day moving average of \$5.62 USD.[33, 46] The short-term outlook is cautiously constructive, but price action remains highly sensitive to regulatory announcements, billing updates, and sequential volume trends in the upcoming second-half 2026 earnings reports.[5, 28]
TECHNICAL UPTREND SUSTAINED
View Myriad Genetics, Inc. (MYGN) stock page
Loading the interactive version of this report…